TIGIT bispecific program is advancing in clinical trials for non-small cell lung and gastric cancers. – Agenus

Agenus shared on LinkedIn:

“Our partner, Bristol Myers Squibb, unveiled exciting updates at their recent R&D Day about their TIGIT bispecific program, which was licensed from Agenus in 2021. This is a differentiated bispecific antibody that potentially enhances the quality and magnitude of immune responses by targeting TIGIT and CD96. The program is advancing in clinical trials for non-small cell lung and gastric cancers. We are encouraged by these latest developments and look forward to future updates regarding this program.”

Source: Agenus/LinkedIn